Multiply Labs has successfully raised $75 million in Series B funding aimed at enhancing its robotic manufacturing platform for cell and gene therapies, as well as advanced biologics. This funding round elevates the company's total funding to over $100 million since its inception in 2016.
The significance of this funding lies in Multiply Labs' ability to address the challenges of manual biomanufacturing processes, which can lead to costly contamination and production delays. The company's robotic clusters are designed to integrate seamlessly with existing pharmaceutical equipment, promising a 74% reduction in cost per dose and up to 100 times the throughput compared to manual methods.
Looking ahead, Multiply Labs plans to utilize the new capital to expand its manufacturing capabilities and accelerate product development. The company aims to transition from clinical-stage deployments to commercial-scale production, thereby increasing access to essential therapies for patients. No further timeline was disclosed at the time of publication.
Editor's Note
The recent funding round for Multiply Labs highlights a growing trend in the pharmaceutical industry towards automation and robotics in drug manufacturing. As the demand for advanced therapies increases, companies are under pressure to enhance production efficiency and reduce costs. This shift could significantly impact supply chain dynamics and the competitive landscape in biomanufacturing.
Leave a comment